Y.D. More Investments Ltd Raises Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Y.D. More Investments Ltd increased its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 73.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 1,615,900 shares of the company’s stock after acquiring an additional 683,150 shares during the period. Teva Pharmaceutical Industries comprises 1.8% of Y.D. More Investments Ltd’s portfolio, making the stock its 12th biggest position. Y.D. More Investments Ltd’s holdings in Teva Pharmaceutical Industries were worth $32,641,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Phoenix Financial Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after purchasing an additional 3,533,800 shares in the last quarter. Menora Mivtachim Holdings LTD. increased its holdings in Teva Pharmaceutical Industries by 31.9% during the second quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock valued at $645,148,000 after buying an additional 9,303,978 shares during the period. Harel Insurance Investments & Financial Services Ltd. raised its stake in Teva Pharmaceutical Industries by 12.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after buying an additional 4,306,363 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in Teva Pharmaceutical Industries by 13.6% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 32,582,212 shares of the company’s stock worth $658,161,000 after buying an additional 3,896,790 shares during the period. Finally, Lingotto Investment Management LLP boosted its position in Teva Pharmaceutical Industries by 1.1% during the 2nd quarter. Lingotto Investment Management LLP now owns 28,156,918 shares of the company’s stock valued at $471,910,000 after acquiring an additional 302,975 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 216,892 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the transaction, the insider owned 52,828 shares in the company, valued at approximately $1,517,748.44. This trade represents a 80.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CAO Amir Weiss sold 12,300 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total value of $371,460.00. Following the completion of the transaction, the chief accounting officer directly owned 5,650 shares of the company’s stock, valued at approximately $170,630. This trade represents a 68.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 422,060 shares of company stock valued at $12,254,965 over the last quarter. 0.49% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on TEVA. JPMorgan Chase & Co. upped their price objective on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Bank of America increased their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research report on Friday, January 30th. Finally, Truist Financial lifted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $37.56.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock traded down $1.13 during mid-day trading on Friday, reaching $33.20. 1,517,044 shares of the company traded hands, compared to its average volume of 10,269,570. The firm’s fifty day moving average is $32.49 and its two-hundred day moving average is $24.94. The company has a market capitalization of $38.17 billion, a price-to-earnings ratio of 27.64, a price-to-earnings-growth ratio of 11.42 and a beta of 0.70. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. During the same period in the prior year, the firm earned $0.71 EPS. The firm’s revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.